
    
      The study will be conducted in the form of a multi-center open-label prospective
      observational controlled pilot study. 15 patients under low dose methotrexate treatment and
      15 healthy controls with an indication for yellow fever vaccination will be included. The
      study duration will be 28 days for each subject and will consist of 6 clinical visits on days
      0, 3, 7, 10, 14 and 28.

      YF antibodies will be measured on days 0, 7, 10, 14 and 28; viremia will be measured on days
      3, 7, 10, 14 and 28.
    
  